Jennison Associates
NVCR icon

Jennison Associates’s NovoCure NVCR Stock Holding History

Jennison Associates’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,010
Closed -$516K – 625
2025
Q2 		$516K Sell
29,010
-3,169
-10% -$55.2K ﹤0.01% 540
2025
Q1 		$573K Buy
+32,179
New +$731K ﹤0.01% 539
2020
Q2 		– Sell
-13,201
Closed -$889K – 678
2020
Q1 		$889K Sell
13,201
-179
-1% -$14.1K ﹤0.01% 504
2019
Q4 		$1.13M Sell
13,380
-2,754
-17% -$222K ﹤0.01% 515
2019
Q3 		$1.21M Buy
16,134
+102
+0.6% +$8.16K ﹤0.01% 526
2019
Q2 		$1.01M Buy
16,032
+1,940
+14% +$98.3K ﹤0.01% 557
2019
Q1 		$679K Buy
+14,092
New +$678K ﹤0.01% 588

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jennison Associates's NVCR Position: Q3 2025 in Review

Jennison Associates sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 29,010 shares — an estimated $516K sold.

Jennison Associates first reported a position in NVCR in Q1 2019 and held it in 7 quarters. The position peaked at $1.21M in Q3 2019. 245 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

  • Jennison Associates reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
  • Jennison Associates sold 29,010 NovoCure shares in Q3 2025, an estimated $516K.
  • Jennison Associates first reported a position in NovoCure in Q1 2019 and held it in 7 quarters.
  • Jennison Associates's NovoCure position peaked at $1.21M in Q3 2019.
  • 245 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Jennison Associates's 13F filing for Q3 2025, filed 30 Oct 2025.